For the first quarter 2024, Celularity expects combined net sales of $14.8 million for its advanced biomaterial product and biobanking businesses, compared to the$10.25 million to $11.5 million guidance range previously announced in February. Celularity's expected combined net sales for the first half 2024 are$25.8 to $27.8 million compared to$6.9 million of net sales in the first of 2023 at the midpoint of the 2024 range. Celularity reiterated it is on track to file a 510(k) premarket submission for its ...